Elucid Bioimaging Inc.

Contact: Andrew Buckler  
Location: Wenham, MA  
Email: andrew.buckler@elucidbio.com  
Tel: 978.468.0508  
Website: http://www.elucidbio.com

**Company Profile**

**Industry Sector:** Software publisher under NAICS code 511210, and services for R&D in biotechnology under code 541711

**Company Overview:** We develop sophisticated products and services to better inform medical decisions, personalize therapy, and provide effective markers for drug development. We facilitate the shift of in-vivo imaging from subjective/qualitative interpretation to quantitative analytical measurement. Elucid creates value and grows revenue with sustainable market leverage to provide a competitive edge in the marketplace based on our patented disruptive technology.

**Target Market(s):** Major Hospitals and clinics

**Key Value Drivers**

**Technology:** Hierarchical Inference: Imaging to Biology to Clinical implemented in Cloud based, Zero Footprint Client, SPARQL Endpoint.

**Competitive Advantage:** Computer-aided phenotyping (CAP) of disease is a new and exciting complement to the field of computer-aided diagnosis (CAD). CAP applies hierarchical inference incorporating computerized image analysis and data fusion algorithms to provide a multi-factorial panel of measurements that may be used to distinguish between different subtypes of disease that would be treated differently.

**Plan & Strategy:** vascuCAP first, lungCAP second, grow out the application base from the platform investment.

**Management**

**Leadership:** Andrew J. Buckler, President/CEO and David Paolino, Executive Director

**Scientific Advisory Board:** Dr. Antonio Gotto, Dean Emeritus, Weill Cornell Medical College, NY NY. Dr. Larry H. Hollier, Vascular Surgeon and Chancellor, Louisiana State University Health Sciences Center (LSUHSC), New Orleans, LA. Dr. Rene Botnar, Head, Biomedical Engineering Department, Professor of Cardiovascular Imaging, King's College, London. Dr. Botnar received his PhD from the ETH Zurich.

**Product Pipeline**

1. **Pipeline One:** vascuCAP: CT for peripheral vessels extended to MR modality, and coronary applications.

2. **Pipeline Two:** lungCAP for lung cancer screening with extensions for use in advanced disease and COPD.

3. **Pipeline Three:** additional applications in kidney disease and heart disease.